Publications

Wang F, Namuju OC, Pastick KA, Abdusalaamu K, Mishra U, Collins L, Boulware DR, Lukande R, Meya DB, Nicol MR. A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues. J Antimicrob Chemother. 2022 Sep 14:dkac300. doi: 10.1093/jac/dkac300. Epub ahead of print. PMID: 36101483.

Lantz A, Nicol MR. Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women. AIDS Res Hum Retroviruses. 2022 Sep 13. doi: 10.1089/AID.2022.0057. Epub ahead of print. PMID: 36097755.

Pastick KA, Nicol MR, Smyth E, Zash R, Boulware DR, Rajasingham R, McDonald EG. A systematic review of treatment and outcomes of pregnant women with COVID-19-a call for clinical trials. Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa350. https://academic.oup.com/ofid/article/7/9/ofaa350/5892324

Skipper C, Atukunda M, Stadelman A, Engen N, Bangdiwala A, Hullsiek KH, Abassi M, Rhein J, Nicol MR, Laker E, Williams DA, Mannino R, Matkovits T, Meya DB, Boulware DR. Phase 1 EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B. Antimicrob Agents Chemother. 2020 Sep 21;64(10). https://aac.asm.org/content/64/10/e00838-20.long

Eneh PC, Hullsiek KH, Kiiza D, Rhein JR, Meya DB, Boulware DR, Nicol MR. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients with suspected meningitis in Uganda. BMC Infectious Disease. 2020 Aug 5;20(1):572.

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05296-w

Takahashi T, Luzum JA, Nicol MR, Jacobson PA. Pharmacogenomics of COVID-19 therapies. NPJ Genom Med. 2020;5:35. doi: 10.1038/s41525-020-00143-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435176/

Nicol MR, Joshi A, Rizk ML, Sabato PE, Savic RM, Wesche D, Zheng JH, Cook J. Pharmacokinetics and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID-19 infection. Clin Pharmacol Ther. 2020 Jul 20;10.1002/cpt.1993. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1993

Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR. Hydroxychloroquine in nonhospitalized adults with early COVID-19. Annals Intern Med. 2020 Jul 16. https://www.acpjournals.org/doi/10.7326/M20-4207

Nicol MR, Cottrell ML, Corbett AH, Chinula L, Tegha G, Stanczyk FZ, Hurst S, Kourtis AP, Tang JK. Endogenous hormones and antiretroviral exposure in plasma, cervicovaginal fluid, and upper-layer packed cells of Malawian women living with HIV. AIDS Res Hum Retrovir. 2020 Aug;36(8):641-646. https://www.liebertpub.com/doi/10.1089/aid.2019.0278

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Cheng MP, LaBar D, Abassi M, Engen NW, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH. A randomized trial of hydroxychloroquine as post-exposure prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383(6):517-525 https://www.nejm.org/doi/full/10.1056/NEJMoa2016638

Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, Rajasingham R, Young J, Nicol MR. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clin Pharmacol Ther. 2020 Oct;108(4):766-769. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1874

Pastick KA, Okafor E, Wang F, Lofgren S, Skipper C, Nicol MR, Pullen M, Rajasingham R, McDonald EG, Lee TC, Schwartz IS, Kelly LE, Lother SA, Mitja O, Letang E, Abassi M, Boulware DR. Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 15April2020. https://academic.oup.com/ofid/article/7/4/ofaa130/5820538

Bohan KH, Flores E, Rajab K, Nambatya W, Nicol M, Crowe S, Manning DH, Eneh P, Odoi Adome R. Improving pharmaceutical care education in Uganda through sustainable experiential programs and research. J Amer Coll Clin Pharm. 2020; 3: 1085– 1096.

Pastick KA, Bangdiwala A, Abassi M, Flynn A, Morawski BM, Musubire A, Eneh PC, Schutz C, Taseera K, Rhein JR, Hullsiek KH, Nicol MR, Vidal JE, Nakasujja N, Meintjes G, Muzoora C, Meya DB, Boulware DR. Seizures in HIV- positive cryptococcal meningitis: predictors and outcomes. Open Forum Infect Dis. 2019;6(11). https://academic.oup.com/ofid/article/6/11/ofz478/5613202

Pittenger AL, Goodroad B, Nicol MR, Durgin E, Eveland L, Kaiser R, Benbenek M, Benson N, Rybicki S. Interprofessional education elective to improve the care for people living with HIV/AIDS. Am J Pharm Educ. 2019; 83 (10):7402 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983904/

Alhadab AA, Rhein J, Tugume L, Musubire A, Williams DA, Abassi M, Nicol MR, Meya DV, Boulware DR, Brundage RC on behalf of ASTRO-CM Study Team. Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. J Pharmacokinet Pharmacodyn. 2019; 46(6):565-576.

Chesdachai S, Rajasingham R, Nicol MR, Meya DB, Bongomin F, Abassi M, Skipper C, Kwizera R, Rhein J, Boulware DR. Minimum inhibitory concentration distribution of fluconazole against Cryptococcus species and the fluconazole exposure prediction model. Open Forum Infect Dis. 2019;6(10). https://academic.oup.com/ofid/article/6/10/ofz369/5550889

Rhein J, Hullsiek KH, Tugume L, Nuwagira E, Mpoza E, Evans EE, Kiggundu R, Pastick KA, Ssebambulidde K, Akampurira A, Williams DA, Bangdiwala A, Abassi M, Musubire A, Nicol MR, Muzoora C, Meya DB, Boulware DR, on behalf of the ASTRO-CM study team. Adjunctive sertraline in HIV-associated cryptococcal meningitis: a randomized, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 2019; 19:843-51.

Nicol MR, Pastick KA, Taylor J, Namuju OC, Rhein J, Williams DA, Meya DB, Boulware DR, Lukande R. Cerebrospinal fluid and brain tissue penetration of tenofovir, lamivudine, and efavirenz in postmortem tissues with cryptococcal meningitis. Clin Transl Sci. 2019 ;12(5)445-449. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12661

Nicol MR, Eneh P, Nakalega R, Kaiser T, Kabwigu S, Isingel E, Beksinska M, Sykes C, Fowler MG, Brown TT, Staley C, Kiweewa Matovu F. Depot medroxyprogesterone acetate and the vaginal microbiome as modifiers of tenofovir diphosphate and lamivudine triphosphate concentrations in the female genital tract of Ugandan women: Implications for TDF/3TC in pre-exposure prophylaxis. Clin Infect Dis. 2019 May 25. pii: ciz443. doi: 10.1093/cid/ciz443. [Epub ahead of print].

Adams JL, Shelley K, Nicol MR. Review of real-world implementation data on emtricitabine/tenofovir disoproxil fumarate as HIV pre-exposure prophylaxis in the United States. SIDP Insight Article. Pharmacother. 2019; 39(4):486-500.

Ellis J, Eneh PC, Ssebambulidde K, Rutakingirwa MK, Lamorde M, Rhein J, Cresswell FV, Boulware DR, Nicol MR. Three’s a crowd: Diagnostic and pharmacokinetic challenges in HIV-TB meningitis-malaria co-infection. A case report. Wellcome Open Res. 2019, 3:111 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343228/

Nicol MR, Corbino J, Cottrell ML. Antiretroviral pharmacology in the female genital tract for HIV prevention. J Clin Pharmacol. 2018;58(11):1381-1395. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333200/

Nicol MR, Brewers LM, Kashuba ADM, Sykes DC. Role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. AIDS. 2018;32 (1):11-5. PMID: 29112071.

Nicol MR, Emerson CW, Fedoriw Y, Nelson JA, Sykes DC, Geller EJ, Prince HA, Patterson KB, Cohen M, Kashuba ADM. Models for Predicting Effective HIV Chemoprevention in Women. J Acquir Immune Defic Syndr. 2015 Apr; 68(4):369-376.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334725/

Thompson CG, Sedykh A, Nicol MR, Muratov E, Fourches D, Tropsha A, Kashuba ADM. Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. AIDS Res Hum Retroviruses. 2014 Nov; 30 (11):1058-64.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208595/

Nicol MR, Fedoriw Y, Mathews M, Prince HMA, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba ADM. Expression of Six Drug Transporters in Vaginal, Cervical, and Colorectal Tissues: Implications for Drug Disposition in HIV Prevention. J Clin Pharmacol 2014 May; 54(5):574-83

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061289/

Nicol MR, Adams JL, Kashuba ADM. HIV pre-exposure prophylaxis trials: the road to success. Clin Invest. 2013 March; 3(3): 295-308.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882078/

Nicol MR, Kashuba ADM. Pharmacologic Opportunities for HIV Prevention. Clin Pharmacol Ther. 2010 Nov;88(5):598-609.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673704/